4.16

1.89% -0.08

After Hours: 4.18 0.02 +0.48%

Eagle Pharmaceuticals Inc (EGRX)

Overview News Price History Option Chain Discussions Forecast

Eagle Pharmaceuticals Inc stock is currently priced at $4.16, with a 24-hour trading volume of 79,461. It has seen a -1.89% decreased in the last 24 hours and a -17.46% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $4.31 pivot point. If it approaches the $4.12 support level, significant changes may occur.

Previous Close:

$4.24

Open:

$4.25

24h Volume:

79,461

Market Cap:

$53.91M

Revenue:

$257.55M

Net Income/Loss:

$11.95M

P/E Ratio:

4.5714

EPS:

0.91

Net Cash Flow:

$-9.39M

1W Performance:

-9.76%

1M Performance:

-17.46%

6M Performance:

-69.52%

1Y Performance:

-84.98%

1D Range:

$4.05

$4.25

52W Range:

$4.05

$30.40

Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile

Name

Eagle Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

201-326-5300

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ

Employee

108

Twitter

@eaglepharm

Next Earnings Date

2024-05-07

Latest SEC Filings

EGRX's Discussions on Twitter

Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Nov-01-18	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-18	Downgrade	Piper Jaffray	Overweight → Neutral
Mar-21-18	Reiterated	Mizuho	Underperform
Nov-09-17	Reiterated	RBC Capital Mkts	Outperform
Sep-06-17	Reiterated	Mizuho	Underperform
Jul-27-17	Reiterated	Mizuho	Underperform
Jul-27-17	Reiterated	RBC Capital Mkts	Outperform
May-09-17	Reiterated	RBC Capital Mkts	Outperform
Jan-09-17	Downgrade	Mizuho	Neutral → Underperform
Nov-16-16	Downgrade	Mizuho	Buy → Neutral
Nov-03-16	Upgrade	Mizuho	Neutral → Buy
Nov-03-16	Reiterated	RBC Capital Mkts	Outperform
Oct-26-16	Reiterated	Mizuho	Buy
Aug-16-16	Reiterated	Mizuho	Neutral
Jun-20-16	Downgrade	Mizuho	Buy → Neutral
May-10-16	Reiterated	RBC Capital Mkts	Outperform
Mar-18-16	Reiterated	Mizuho	Buy
Feb-26-16	Reiterated	Mizuho	Buy
Dec-09-15	Initiated	Mizuho	Buy
Jul-29-15	Reiterated	Piper Jaffray	Overweight

View All

Eagle Pharmaceuticals Inc Stock (EGRX) Latest News

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

GlobeNewswire Inc.

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

GlobeNewswire Inc.

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

GlobeNewswire Inc.

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

GlobeNewswire Inc.

Eagle Pharmaceuticals Announces Management Change

GlobeNewswire Inc.

Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data

Eagle Pharmaceuticals Inc (EGRX) Revenue 2024

EGRX reported a revenue (TTM) of $257.55 million for the quarter ending June 30, 2023, a -5.38% decline year-over-year.

Eagle Pharmaceuticals Inc (EGRX) Net Income 2024

EGRX net income (TTM) was $11.95 million for the quarter ending June 30, 2023, a -47.57% decrease year-over-year.

Eagle Pharmaceuticals Inc (EGRX) Cash Flow 2024

EGRX recorded a free cash flow (TTM) of -$9.39 million for the quarter ending June 30, 2023, a -126.60% decrease year-over-year.

Eagle Pharmaceuticals Inc (EGRX) Earnings per Share 2024

EGRX earnings per share (TTM) was $0.91 for the quarter ending June 30, 2023, a -48.30% decline year-over-year.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.